High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: Results from the TOLERANCE study

International Journal of Clinical Practice

Volumn 62, Issue 5, 2008, Pages 723-728

  Barrios, V ^a   Escobar, C ^b   De La Figuera, M ^c   Honorato, J ^d   Llisterri, J L ^e   Segura, J ^f   Calderon A ^g  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c CAP La Mina   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e C S Ingeniero Joaquín Benlloch   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Centro de Salud Rosa Luxemburgo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LERCANIDIPINE; NIFEDIPINE;

ADULT; AGED; ANKLE EDEMA; ARTICLE; CLINICAL PRACTICE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SWELLING; TREATMENT OUTCOME; TREATMENT RESPONSE; VASODILATATION;

ADOLESCENT; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-SECTIONAL STUDIES; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIFEDIPINE;

EID: 42149191496     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01736.x     Document Type: Article

References (39)

1. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006 332 : 878 82.
2. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006 119 : S3 9.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 414 : 782 7.
4. Cuspidi C, Meani S, Valerio C et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 2007 20 : 296 303.
5. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007 49 : 403 14.
6. Mule G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich) 2006 8 : 195 201.
7. de Simone G, Olsen MH, Wachtell K et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 2007 21 : 625 32.
8. Mancia G, De BackerG, Dominiczak A et al. Guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 25 : 1105 87.
9. Barrios V, Escobar C, Calderon A et al. Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr 2007 2 : 9 15.
10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 97.
11. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003 63 : 2449 72.
12. Barrios V, Navarro A, Esteras A et al. Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002 11 : 95 100.
13. Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002 40 : 133 9.
14. Barrios V, Escobar C, Navarro A et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int J Clin Pract 2006 60 : 1364 70.
15. Barrios V, Escobar C, Calderon A, Navarro A, Ruilope LM. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br J Cardiol 2006 13 : 433 40.
16. Barrios V, Escobar C, Navarro A, Calderon A, Ruilope LM. Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study. Therapy 2007 4 : 433 40.
17. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002 16 : 605 10.
18. Millar-Craig M, Shaffu B, Greenough A, Mitchell L, McDonald C. Lercanidipine vs. lacidipine in isolated systolic hypertension. J Hum Hypertens 2003 17 : 799 806.
19. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006 24 : 185 92.
20. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002 15 : 932 40.
21. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005 27 : 73 80.
22. Barrios V, Escobar C, de la Figuera M et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice. The TOLERANCE Study. Cardiovasc Drug Rev 2008 (in press).
23. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 21 : 1011 53.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 421.
25. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. The interpretation of diagnostic data. In : Sackett DL, Haynes RB, Guyatt GH, Tugwell P, eds. Clinical epidemiology: a basic science for clinical medicine, 2nd edn. Boston : Little Brown, 1991 : 69 152.
26. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 9.
27. Barrios V, Escobar C, Calderón A, Echarri R, González-Pedel V, Ruilope LM. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007 21 : 479 85.
28. De la Sierra A, Romero R, Bonet J et al. Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population. Med Clin (Barc) 2006 126 : 406 9.
29. Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J Hypertens 2007 25 : 1975 7.
30. Mino-León D, Reyes-Morales H, Galván-Plata ME et al. Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting. Rev Invest Clin 2007 59 : 8 14.
31. Rosser WW. Application of evidence from randomised controlled trials to general practice. Lancet 1999 353 : 661 4.
32. Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007 167 : 68 73.
33. Meredith PA. Lercanidipine: a novel lipohilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs 1999 8 : 1043 62.
34. Angelico P, Guarnieri N, Leonardi A, Testa R. Vascular-selective effect of lercanidipine and other 1,4 dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999 51 : 709 14.
35. Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in post-menopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003 21 : 1003 10.
36. Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003 16 : 596 9.
37. Grassi G, Serravalle G, Turri C, Bertinieri G, Stella ML, Mancia G. Different behaviour of the sympathetic responses to acute and chronic blood pressure reductions induced by antihypertensive drugs. J Hypertens 1998 16 : 1357 69.
38. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003 1 : 14 21.
39. Roth MT, Ivey JL. Self-reported medication use in community-residing older adults: A pilot study. Am J Geriatr Pharmacother 2005 3 : 196 204.